Biogen Inc. (FRA:IDP)

Germany flag Germany · Delayed Price · Currency is EUR
126.90
+0.75 (0.59%)
Last updated: Oct 21, 2025, 10:32 AM CET
0.59%
Market Cap18.46B
Revenue (ttm)8.51B
Net Income (ttm)1.30B
Shares Outn/a
EPS (ttm)8.90
PE Ratio14.17
Forward PE9.49
Dividendn/a
Ex-Dividend Daten/a
Volume370
Average Volume365
Open125.85
Previous Close126.15
Day's Range125.85 - 127.00
52-Week Range99.82 - 174.20
Betan/a
RSI54.17
Earnings DateOct 30, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1978
Employees 7,605
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol IDP
Full Company Profile

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD Financial Statements

News

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround

Key PointsFlorida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter.

2 days ago - Nasdaq

Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy

Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy

4 days ago - GuruFocus

Why InnoCare's Licensing Deal Triggered A Stock Rout

The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print Key Takeaways: The counterparty, Zenas ...

5 days ago - Benzinga

Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact

Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact

7 days ago - GuruFocus

LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CE...

8 days ago - Wallstreet:Online

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

TOKYO and CAMBRIDGE, Mass. , Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Headquarters: Cambridge, Massachusetts , C...

8 days ago - Benzinga

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CE...

8 days ago - GlobeNewsWire

BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BIIB Stock News

BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BIIB Stock News

11 days ago - GuruFocus

Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome

(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorevunersen, reinforcing its potential as a ...

12 days ago - Nasdaq

BIIB: New Findings Highlight the Potential of Zorevunersen for Dravet Syndrome

BIIB: New Findings Highlight the Potential of Zorevunersen for Dravet Syndrome

12 days ago - GuruFocus

Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Syndrome

Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Syndrome

12 days ago - GuruFocus

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal c...

12 days ago - GlobeNewsWire

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...

12 days ago - Business Wire

Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation

Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation

14 days ago - GuruFocus

Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug

Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug

15 days ago - GuruFocus

Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment

(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for maintenance dosing in ...

15 days ago - Nasdaq

Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S.

Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S.

15 days ago - GuruFocus

Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S.

Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S.

15 days ago - GuruFocus

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...

15 days ago - Benzinga

Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

New LEQEMBI Companion program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an inj...

15 days ago - Wallstreet:Online

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...

15 days ago - PRNewsWire

Monday Sector Laggards: Healthcare, Consumer Products

The worst performing sector as of midday Monday is the Healthcare sector, showing a 0.6% loss. Within that group, Biogen Inc (Symbol: BIIB) and Baxter International Inc (Symbol: BAX) are two of the da...

15 days ago - Nasdaq